最新ニュース Icon (NASDAQ:ICLR) 株価情報

Icon

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Icon PLC

Barclays analyst Luke Sergott maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Equal-Weight and lowers the price target from $165 to $155.

News

Price Target

Analyst Ratings

ICLR

Barclays Maintains Equal-Weight on Icon, Lowers Price Target to $155

Goldman Sachs analyst Matthew Sykes maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $180 to $160.

Goldman Sachs Maintains Neutral on Icon, Lowers Price Target to $160

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $192 to $160.

Baird Maintains Neutral on Icon, Lowers Price Target to $160

WIIM

Icon shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, the company lowered its FY25 guidance.

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) lowers FY2025 Adj EPS guidance from $13.00-$15.00 to $12.75-$14.25 vs $13.66 analyst estimate. Lowers FY2025 sales outlook from $8.05 billion-$8.65 billion to $7.75 billion-$8.15 billion vs $8.25 billion estimate.

Guidance

Icon Lowers FY2025 Adj EPS Guidance from $13.00-$15.00 to $12.75-$14.25 vs $13.66 Est; Lowers FY2025 Sales Guidance from $8.05B-$8.65B to $7.75B-$8.15B vs $8.25B Est

Icon shares are trading lower after the company reported worse-than-expected Q1 sales results.

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) reported quarterly earnings of $3.19 per share which beat the analyst consensus estimate of $3.13 by 1.92 percent. This is a 8.07 percent decrease over earnings of $3.47 per share from the same period last year. The company reported quarterly sales of $2.00 billion which missed the analyst consensus estimate of $2.02 billion by 0.79 percent. This is a 4.26 percent decrease over sales of $2.09 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Icon Q1 Adj. EPS $3.19 Beats $3.13 Estimate, Sales $2.00B Miss $2.02B Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Casey Woodring downgraded the rating for ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Overweight to Neutral and lowered the price target from $265 to $150. Icon shares closed at $145.00 on Monday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Mike Polark downgraded Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) from Outperform to Peer Perform. Insulet shares closed at $259.52 on Monday. <a href="https://www.benzinga.com/quote/PODD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Daniel Imbro downgraded Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) from Overweight to Equal-Weight and lowered the price target from $515 to $255. Saia shares closed at $237.11 on Monday. <a href="https://www.benzinga.com/quote/SAIA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Pablo Monsivais downgraded the rating for Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) from Overweight to Equal-Weight and slashed the price target from $12 to $4.5. Controladora Vuela shares closed at $3.94 on Monday. <a href="https://www.benzinga.com/quote/VLRS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SAIA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213-1024x589.png" alt="" class="wp-image-892692" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45060164/general-motors-coca-cola-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

PODD

SAIA

VLRS

This Saia Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

JP Morgan analyst Casey Woodring downgrades Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Overweight to Neutral and lowers the price target from $265 to $150.

JP Morgan Downgrades Icon to Neutral, Lowers Price Target to $150

TD Cowen analyst Charles Rhyee downgrades Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Buy to Hold and lowers the price target from $254 to $157.

TD Cowen Downgrades Icon to Hold, Lowers Price Target to $157

Truist Securities analyst Jailendra Singh maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $262 to $208.

Truist Securities Maintains Buy on Icon, Lowers Price Target to $208

Barclays analyst Luke Sergott downgrades Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Overweight to Equal-Weight and lowers the price target from $240 to $165.

Barclays Downgrades Icon to Equal-Weight, Lowers Price Target to $165

Mizuho analyst Ann Hynes maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $238 to $200.

Mizuho Maintains Outperform on Icon, Lowers Price Target to $200

Citigroup analyst Patrick Donnelly maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $290 to $215.

Citigroup Maintains Buy on Icon, Lowers Price Target to $215

Goldman Sachs analyst Matthew Sykes downgrades Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Buy to Neutral and lowers the price target from $250 to $200.

Goldman Sachs Downgrades Icon to Neutral, Lowers Price Target to $200

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $221 to $203.

Baird Maintains Neutral on Icon, Lowers Price Target to $203

Contracts

Mural Health Technologies Enters Partnership With ICON To Utilize Mural Link For Trial Payments, Travel Support, And Communication Tools

Icon shares are trading lower after the company announced delays in covid vaccine study.

Barclays analyst Luke Sergott maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $275 to $240.

Barclays Maintains Overweight on Icon, Lowers Price Target to $240

Press Releases

The Gross Law Firm Reminds ICON  Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2025 - ICLR

ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Legal

ICON Public Limited Company Class Action: Levi & Korsinsky Reminds ICON Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2025 – ICLR

Class Action Filed Against ICON Public Limited Company (ICLR) Seeking Recovery for Investors - Contact Levi & Korsinsky

ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm

ICON Reports First Quarter 2025 Results

ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall LAW FIRM

Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

Comments

Icon

ニュース

最新ニュース Icon (NASDAQ:ICLR) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル